Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2877127 | The Annals of Thoracic Surgery | 2011 | 9 Pages |
Abstract
Patients who undergo resection of residual lung or mediastinal disease for metastatic testicular NSGCT as a planned approach after cisplatin-based chemotherapy have overall excellent long-term survival. Survival is equivalent comparing hematogenous and lymphatic routes of metastases but depends on the pathology of the resected disease. These results justify an aggressive surgical approach, particularly to remove residual teratoma in the lung or mediastinum after chemotherapy, including multiple surgical procedures if necessary.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Kenneth A. MD, Laura E. MD, Susan M. PhD, Karen M. MD, Katherine J. MD, Matthew L. MD, John W. MD, Lawrence H. MD,